SONIA ESPARZA HEPBURN M.D. NPI 1760800858

NPI Details

Sonia Esparza Hepburn, M.D. is a hematology and oncology internal medicine in Williamsburg, VA with 12 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Sonia Esparza Hepburn, M.D. NPI is 1760800858. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UNIVERSITY OF SOUTHERN CALIFORNIA KECK SCHOOL OF MEDICINE
Graduation Year:2014

The provider's business location address is:

500 SENTARA CIR STE 203
WILLIAMSBURG, VA
ZIP 23188-727
Phone: (757) 229-2236
Fax: (757) 221-0409

The NPI 1760800858 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Measurement of substance using immunoassay technique (HCPCS:83520)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Ferritin (blood protein) level (HCPCS:82728)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Protein measurement, serum (HCPCS:84165)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Unclassified drugs (HCPCS:J3490)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Red blood count automated, with additional calculations (HCPCS:85046)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Uric acid level, blood (HCPCS:84550)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Folic acid level, serum (HCPCS:82746)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Drawing of blood for a medical problem (HCPCS:99195)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)

The enumeration date for this NPI number is 4/4/2014 and was last updated on 6/10/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.